To Correlate The Serum Zinc And C-Peptide Levels In Patients With Type II Diabetes Mellitus With And Without Complications
To Correlate The Serum Zinc And C-Peptide Levels In Patients With Type II Diabetes Mellitus
Keywords:
Diabetes mellitus, Serum Zn, C-peptide levelAbstract
Aims: Two prime leads that led to the present work are firstly, disturbances in Zinc metabolism are more pronounced in diabetics with complication and secondly, diabetic patient with increased C-peptide have an increased risk of coronary heart disease and peripheral vascular diseases. The aim of the study is to observe whether serum Zinc and /or C-peptide levels have any correlation in patients of type 2 diabetes mellitus (DM) with or without complications. Material and Methods: This prospective study included all newly diagnosed cases of type 2 DM with or without complications, of either sex between 30 to 80 yrs. Patients were clinically assessed and investigated, and their serum Zn and C-peptide levels were determined. Statistical analysis was carried out using unpaired students t-test. Results: During two year study period, 96 newly diagnosed consecutive type 2 DM cases were enrolled and they were divided into two groups. Group I included cases of DM without complications (n=54) and Group II cases of DM with complications (n=42). Neuropathy was present in 34 cases, nephropathy in 26 cases and retinopathy in 20 cases and all three complications were present in 10 cases. Mean serum Zn levels although slightly lower 70.96+1.54 μg/dl in group II cases compared to group I 72.28 +4.06 μg/dl was found statistically insignificant. Similarly mean serum C-peptide levels in group II (13.91+5.60 ng/ml) and group I (12.80+3.61 ng/ml) did not show a statistically significant alterations. Conclusion: It is concluded that serum Zn level and C-peptide levels bear no correlation and are of no predictive value in cases of type 2 diabetes mellitus with or without complications.
References
2. Nsonwu AC, Usoro CAO, Etukudo MH, Usoro IN. Glycemic control and serum and urine levelsof zinc and magnesium in diabetes in Calabar, Nigeria. Pakistan J Nutr. 2006; 5(1): 75-78.
3. Wahren J. C-peptide: new findings and therapeutic implications in diabetes. Clin Physiol Funct Imaging. 2004; 24(4):180-89.
4. Klein R, Klein BE, Moss SE. The Wisconsin Epidemiologic Study of diabetic retinopathy XVI. The relationship of C-peptide to the incidence and progression of diabetic retinopathy. Diabetes 1995; 44: 796-801.
5. Inukai T, Matsutomo R, Tayama K, Aso Y, Takemura Y. Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 1999; 107: 40-45.
6. Sari R, Balci MK. Relationship between C-peptide and chronic complications in type 2 diabetes mellitus. J Natl Med Assoc 2005; 97(8): 1113-18.
7. Bo S, Cavallo-Perin P, Gentile L, et al. Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetol 2000;37:125-29.
8. Winocour PH, Jeacock J, Kalsi P, et al. The relevance of persistent C-peptide secretion in type 1 (insulin-dependent) diabetes mellitus to glycemic control and diabetic complications. Diabetes Res Clin Pract 1990;9:23-35.
9. U.K Prospective Study (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53.
10. Walter RM, Uriu Hare JY, Olin KL, et al. Cu, Zn, Mn, and Mg status and complications of diabetes mellitus. Diabetes care 1991; 14(1):1050-56.
11. Car N, Car A, Granic M, et al. Zinc and Copper in the serum of diabetic patients. Biol Trace Elem Res 1992; 32:325-29.
12. Chausmer AB. Zinc, Insulin and diabetes. J Am Coll Nutr 1998; 17:109-14.
13. D’Ocon C, Alonso DAV, Frasquet I. Levels of zinc and Cu in the serum of a diabetic population. Rev Esp Fisiol 1987; 43(3): 335-38.
14. Toyry JP, Niskanen LK, Mantysaari MJ, et al. Do high proinsulin and C-peptide levels play a role in autonomic nervous dysfunction: Power spectral analysis in patients with non-insulin dependent diabetes and non-diabetic subjects. Circulation. 1997; 96: 1185-91.
15. Gottsater A, Kangro M, Sundkvistt G. Early parasympathetic neuropathy associated with elevated fasting plasma C-peptide concentrations and late parasympathetic neuropathy with hyperglycaemia and other microvascular complications. Diabetes Medicine 2004, 21: 1304-09.
16. Shin SJ, Lee YJ, Hsaio PJ, et al. Relationships between β-cell function and diabetic duration and albuminuria in type 2 diabetes mellitus. Pancreas.1997; 14: 192-98.
